Menu Close

Articles on RSV

Displaying all articles

Healthy, full-term Inuit babies are not eligible for palivizumab even though they have four to 10 times the rate of hospital admission compared to “high-risk” infants. (Philippe Put/flickr)

Inuit infants need access to medication to prevent respiratory illness

A drug called palivizumab can keep babies infected with respiratory syncytial virus (RSV) out of the hospital, but many Inuit babies, who have a higher risk of infection, are not getting it.

Top contributors